After Myriad, what makes a gene patent claim 'markedly different' from nature?

Nature Biotechnology 35, 820 (2017). doi:10.1038/nbt.3953 Authors: Mateo Aboy, Johnathon Liddicoat, Kathleen Liddell, Matthew Jordan & Cristina Crespo Examining the types of claim amendments that have transformed isolated gene claims from patent-ineligible into eligible subject matter provides clarity into the threshold of eligibility for gene-related patents.
Source: Nature Biotechnology - Category: Biotechnology Authors: Tags: Feature Source Type: research